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Objectives The aim of this study was to investigate whether there is a temporal pattern of ischemic events in relation to
dual antiplatelet therapy in patients with unprotected left main coronary artery (ULMCA) stenosis treated with
percutaneous coronary intervention (PCI).
Background Identifying which periods during follow-up of patients with ULMCA stenosis treated with PCI are associated with
higher risk of clinical events might help to improve therapeutic strategies.
Methods We analyzed data from 15 centers involved in an observational study conducted by the Italian Society of Invasive
Cardiology on patients with ULMCA stenosis treated with PCI. Eight hundred ninety-four patients were enrolled.
Results At 30-day follow-up, the rate of cardiac mortality and myocardial infarction (MI) was 5.4%. In patients still taking
dual antiplatelet therapy, the adjusted incidence rate ratio/10,000 patient-days of the combination of cardiac
mortality and MI in the 31- to 180-day interval compared with the 181- to 360-day interval after PCI was 3.64
(p  0.035). This risk was particularly high in patients with acute coronary syndromes. After stopping clopi-
dogrel, the adjusted incidence rate ratio of cardiac mortality and MI in the 0- to 90-day interval compared with
the 91- to 180-day interval was 4.20 (p  0.009).
Conclusions In patients with ULMCA stenosis taking dual antiplatelet therapy there is an increased hazard of cardiac mortal-
ity and MI between 31 and 180 days compared with 181 to 360 days. Furthermore, there is an increased haz-
ard of cardiac mortality and MI in the first 90 days after stopping clopidogrel. (J Am Coll Cardiol 2009;53:
1176–81) © 2009 by the American College of Cardiology Foundation
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April 7, 2009:1176–81 Ischemic Events in Left Mainhe introduction of stents and, more recently, drug-eluting
tents has renewed the interest in the percutaneous treatment
f unprotected left main coronary artery (ULMCA) stenosis
1). Several studies have reported very favorable outcomes that
re competitive with surgery, especially for ostial and mid-
haft lesions (2–5). In particular all studies have consistently
hown that the procedural risk of percutaneous coronary
ntervention (PCI) in elective patients is, in general, low and
omparable to that of surgery. However, the risk of sudden
eath and of major ischemic events during follow-up raises
ome concerns and limits the widespread use of PCI in this
ontext (6). A more comprehensive understanding of risks
uring follow-up and in particular of the timing of the risk
f ischemic events in relation to the duration and time of
iscontinuation of clopidogrel therapy might help to im-
rove therapeutic strategies and thus clinical outcomes of
hese patients. Therefore, we investigated how the risk of
ardiac mortality and myocardial infarction (MI) is distrib-
ted over the course of the first year in patients with
LMCA stenosis treated with PCI while they were still
aking dual antiplatelet therapy. Moreover, we also assessed
he incidence of cardiac mortality and MI in the first 9
onths after stopping clopidogrel.
ethods
atients and definitions. The characteristics of the GISE-
ICI (Gruppo Italiano Studi Emodinamici) survey on
LMCA stenosis have been already reported in detail (7).
riefly, this survey was a multicenter, retrospective, obser-
ational study performed in patients with ULMCA stenosis
reated with PCI. All interventional high-volume centers
erforming 800 PCIs/year in Italy and affiliated with
ISE-SICI were asked to participate in the survey by
roviding demographic, clinical, procedural, and follow-up
ata on consecutive patients with ULMCA stenosis treated
ith PCI between January 2002 and December 2006. For
he purpose of this study, we included only those centers
hat systematically collected data on dual antiplatelet ther-
py (15 centers). Patients taking warfarin therapy and those
ith antiplatelet therapies different from clopidogrel and
spirin were excluded. Clinical follow-up was performed
hrough office visits, telephone interviews, or—when pa-
ients could not be contacted either way—by consulting
ivil registries of mortality.
We defined as the clinical end point of interest the
ccurrence of cardiac mortality or MI. In the computation
f this end point, events were counted only once (whichever
ccurred first). Other definitions of the study have been
lready published in detail (7). The study was approved by
he local ethics committees of each participating center.
tatistical analysis. The primary object of the study was to
valuate the association between time interval after PCI and
he incidence of cardiac mortality and MI while patients
ere still taking dual antiplatelet therapy. In this analysis, toliminate periprocedural factors or other conditions associ- fted with the risk of early mor-
ality or MI, we did not consider
vents occurring in the first 30
ays after PCI, censoring all pa-
ients who died or had an MI in
his interval of time. Four peri-
ds of interest were considered:
1 to 90, 91 to 180, 181 to 270,
nd 271 to 360 days after PCI.
nadjusted incidence rates of the clinical end point in the
arious intervals of time were compared with the Fisher
xact test. The incidence rate was calculated considering the
umber of events/10,000 patient-days of treatment. To
inimize possible selection bias, we used a Poisson regres-
ion multivariable analysis in which the variable of interest
as the risk of the clinical end point in the interval of time
etween 31 and 180 days after PCI compared with 181 to
60 days. The following variables were included in the
odel: age, renal dysfunction, acute coronary syndrome,
nd left ventricular ejection fraction. To determine risk
djusted instantaneous incidence rates of events during the
eriod of dual antiplatelet therapy, we performed a multi-
ariable Cox regression analysis, adjusting for the same
ariables as specified in the preceding text and using kernel
azard functions.
Furthermore, we also investigated the association be-
ween the time interval after stopping clopidogrel and the
ncidence of cardiac mortality and MI. After stopping
lopidogrel, 3 periods of interest were considered: 0 to 90,
1 to 180, and 181 to 270 days. We performed a Fisher
xact test to compare incidence rates in the various intervals
f time, a Poisson regression analysis to assess the risk of
ardiac mortality and MI in the first 90 days, and a Cox
egression analysis using kernel hazard functions to deter-
ine the risk-adjusted instantaneous incidence rates of
vents. Statistical analyses were performed with SPSS ver-
ion 12.0 for Windows (SPSS Inc., Chicago, Illinois) and
TATA/SE version 9.2 for Windows (Statacorp, College
tation, Texas). A value of p  0.05 was considered
tatistically significant.
esults
0-day clinical outcomes. Clinical characteristics of the
eneral cohort of patients, of patients suitable for analyses
n dual antiplatelet therapy, and of patients suitable for
nalyses after clopidogrel discontinuation are shown in
able 1. At 30-day follow-up there were 48 clinical end
oint events (5.4%). We observed 30 cardiac deaths (3.3%)
nd 19 MIs (2.1%). The incidence rate of cardiac mortality
nd MI per 10,000 patient-days was 19.1.
linical outcomes on clopidogrel treatment after 30-day
ollow-up. After eliminating patients who died or had an
I in the first 30 days, patients who were prescribed
-month dual antiplatelet therapy, those who were lost to
Abbreviations
and Acronyms
MI  myocardial infarction
PCI  percutaneous
coronary intervention
ULMCA  unprotected left
main coronary arteryollow-up before 30 days, or those who were treated with a
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Ischemic Events in Left Main April 7, 2009:1176–81ombination of dual antiplatelet therapy different from
spirin and clopidogrel, 765 patients remained available for
he evaluation of the clinical outcome on dual antiplatelet
herapy. There were 12 clinical end point events (44%)
etween 31 and 90 days, 12 events in the period between 91
nd 180 days, 3 events (12%) between 181 and 270 days,
nd no events between 271 and 360 days (Table 2). The
nadjusted incidence rate of the clinical end point per
0,000 patient-days was 2.7 for the 31- to 90-day period, 2.3
or the 91- to 180-day period, 1.03 for the 181- to 270-day
eriod, and 0 for the 270- to 360-day period (p  0.029).
igure 1, which represents the instantaneous incidence of
he clinical end point, shows an increased risk of events
linical Characteristics of the General Cohort of Patients Enrollednalyses on Dual Antiplatelet Therapy, and of the Cohort of Patien
Table 1 Clinical Characteristics of the General Cohort of PatienAnalyses on Dual Antiplatelet Therapy, and of the Coh
General Cohort
(n  894)
Age, yrs, median (range) 73 (20–97)
Male 627 (70.2)
Systemic hypertension 624 (70.9)
Diabetes mellitus 251 (28.4)
Hypercholesterolemia 538 (61.3)
Present or previous smoking habitus 300 (34.8)
Family history of coronary disease 178 (26.2)
Acute coronary syndrome 530 (60.2)
Unstable angina 274 (51.7)
NSTEMI 256 (48.3)
Chronic pulmonary disease 91 (13.2)
Renal dysfunction 136 (15.7)
Peripheral vascular disease 176 (25.7)
Euroscore, median (range) 5 (0–18)
LVEF, median (range) 55 (15–80)
Drug-eluting stent 654 (73.1)
Lesion location
Ostium 167 (18.7)
Shaft 88 (9.8)
Bifurcation 639 (71.5)
Multivessel disease 439 (49.3)
Multivessel treatment 265 (29.8)
Glycoprotein IIb/IIIa inhibitors 269 (30.0)
Dual antiplatelet therapy 6 months 234 (26.2)
Dual antiplatelet therapy  6 months 229 (25.6)
Dual antiplatelet therapy 9–12 months 405 (45.3)
Dual antiplatelet therapy 12 months 26 (2.9)
alues are n (%) unless otherwise indicated.
LVEF  left ventricular ejection fraction; NSTEMI  non–ST-segment elevation myocardial infar
umber of Cardiac Deaths, MIs, and the Combination of Cardiac Dr MI While Pat ents Were Taking Dual Antiplatelet Therapy
Table 2 Number of Cardiac Deaths, MIs, and the Combinationor MI While Patients Were Taking Dual Antiplatelet Th
Events 0–30 Days 31–90 D
Cardiac death, n 30
MI, n 19
Cardiac death or MI, n 48 1
Patient-days 25,170 45,13
Incidence rate/10,000 patient-days of
cardiac mortality and MI
19.1I  myocardial infarction.etween 30 and 180 days, this risk abruptly declined
hereafter. Therefore, in the multivariable analysis we con-
idered 2 periods at risk: between 31 and 180 days and
etween 181 and 360 days. The unadjusted incidence rates
er 10,000 patient-days in these 2 periods were 2.5 and 0.6,
espectively (p  0.008). In the multivariable analysis
Table 3), the incidence rate ratio of the clinical end point
etween 31 and 180 days compared with between 181 and
60 days was 3.64 (95% confidence interval: 1.09 to 12.16;
 0.035). As shown in Figure 2, in stable patients the
ncidence rate of the primary end point per 10,000 patient-
ays was 0.2 between 31 and 180 days and 0 between 181
nd 360 days (p  NS). In patients with acute coronary
Study, of the Cohort of Patients Selected forlecte for Analyses After Clopidogrel Discontinuation
nrolled in the Study, of the Cohort of Patients Selected for
Patients Selected for Analyses After Clopidogrel Discontinuation
On Dual Antiplatelet Therapy
(n  765)
After Clopidogrel Discontinuation
(n 641)
72 (20–97) 72 (29–97)
548 (71.7) 463 (72.2)
524 (68.9) 448 (71.1)
215 (28.3) 167 (26.2)
459 (61.2) 397 (63.1)
264 (35.5) 220 (35.6)
159 (26.9) 123 (25.8)
431 (57.0) 365 (57.5)
225 (52.2) 196 (53.7)
206 (47.8) 169 (46.3)
79 (13.1) 60 (12.4)
103 (13.8) 87 (14.0)
143 (23.8) 118 (24.3)
5 (0–18) 5 (0–18)
55 (20–80) 55 (25–80)
610 (79.7) 468 (73.0)
138 (18.0) 118 (18.4)
68 (8.9) 61 (9.5)
559 (73.1) 462 (72.1)
378 (49.7) 308 (48.2)
227 (29.8) 182 (28.5)
237 (31.0) 192 (29.9)
141 (18.4) 202 (31.5)
213 (27.8) 199 (31.1)
392 (51.3) 237 (36.9)
19 (2.5) 3 (0.5)
rdiac Death
91–180 Days 181–270 Days 271–360 Days
8 3 0
5 0 0
12 3 0
52,362 29,204 23,259
2.3 1.03 0in thets Se
ts E
ort ofeath
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erapy
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April 7, 2009:1176–81 Ischemic Events in Left Mainyndromes the incidence rate was 4.2 in the first period and
.1 in the second period (p  0.01).
linical outcome after stopping clopidogrel. For this
nalysis we excluded patients who presented an event in the
rst 30 days, patients with events while taking dual anti-
latelet therapy, and patients who were still taking dual
ntiplatelet therapy at the time of the last contact. A total of
41 patients were suitable for this analysis. During the
-month follow-up, after stopping clopidogrel there were
7 clinical end point events (17 cardiac deaths and 12 MIs).
wenty (74%) of these events (13 cardiac deaths and 8 MIs)
ccurred 0 to 90 days, 5 (19%) occurred 91 to 180 days (3
ardiac deaths and 3 MIs), and 2 (7%) occurred 181 to 270
Figure 1
Adjusted Instantaneous Incidence Rate/Patient-Days
of Cardiac Mortality and MI During the First Year of
Follow-Up in Patients Taking Dual Antiplatelet Therapy
The risk of cardiac mortality and myocardial infarction (MI) was
concentrated between 31 and 180 days; this risk abruptly declined thereafter.
oisson Multivariable Analysis Assessing thencidence Rate R tio of Cardiac Mortality andI During the Cours f Dual AP and Af erlopidogrel Disc n inuation
Table 3
Poisson Multivariable Analysis Assessing the
Incidence Rate Ratio of Cardiac Mortality and
MI During the Course of Dual AP and After
Clopidogrel Discontinuation
Incidence Rate Ratio
(95% Confidence Interval)
p
Value
On dual AP
31–180 days vs. 181–360 days 3.64 (1.09–12.16) 0.035
Age 1.02 (0.97–1.06) 0.46
Acute coronary syndrome 14.2 (1.92–105.79) 0.009
Renal dysfunction 6.89 (3.01–15.78) 0.0001
Left ventricular ejection fraction 0.97 (0.94–1.01) 0.055
Off dual AP
0–90 days vs. 91–180 days 4.20 (1.43–12.30) 0.009
Age 75 yrs 3.76 (1.46–9.65) 0.006
Acute coronary syndrome 3.77 (1.11–12.82) 0.033
Renal dysfunction 3.19 (1.39–7.34) 0.006
Left ventricular ejection fraction 40% 2.25 (0.98–5.17) 0.054
6-month dual AP vs. 6-month dual AP 0.35 (0.12–1.03) 0.06P  antiplatelet therapy; MI  myocardial infarction. Mays after stopping clopidogrel (1 cardiac death and 1 MI).
he unadjusted incidence rate of the clinical end point per
0,000 patient-days was 3.88 between 0 and 90 days, 1.11
etween 91 and 180 days, and 0.49 between 181 and 270
ays (p  0.0001). Although most of the events observed
etween 0 and 90 days after stopping clopidogrel occurred
n patients treated with dual antiplatelet therapy for a period
6 months; a similar pattern of events clustering in the first
months after clopidogrel discontinuation was also ob-
erved for patients treated with clopidogrel for 6 months
nd in those treated for more than 6 months (Table 4).
igure 3, which represents the instantaneous incidence of
he clinical end point after clopidogrel discontinuation,
Figure 2
Incidence Rate of Cardiac Mortality and MI
Between 31 and 180 Days Compared With 181 and
360 Days in Stable Patients or Those With ACS
In stable patients there was 1 event between 31 and 180 days of dual anti-
platelet treatment and no events thereafter. In patients with acute coronary
syndrome (ACS) there were 23 events between 31 and 180 days and only 3
thereafter. MI  myocardial infarction.
ncidence of Cardiac Mortalitynd MI After Stopping Clopidogrel inelation to Du l Antiplatelet Therapy Duration
Table 4
Incidence of Cardiac Mortality
and MI After Stopping Clopidogrel in
Relation to Dual Antiplatelet Therapy Duration
Duration of
Clopidogrel Treatment
0–90
Days
91–180
Days
181–270
Days
p
Value
6 months
Number of events 13 4 1 0.003
Patient-days 17,299 16,490 16,040
 6 months
Number of events 3 1 1 0.64
Patient-days 16,527 14,978 13,312
9–12 months
Number of events 4 0 0 0.07
Patient-days 16,335 12,992 11,100
12 months
Number of events 0 0 0 —
Patient-days 219 90 90
All patients
Number of events 20 5 2 0.0001
Patient-days 50,380 44,555 40,544I  myocardial infarction.
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Ischemic Events in Left Main April 7, 2009:1176–81hows that the risk of events was concentrated in the first 90
ays, abruptly declining thereafter. In the multivariable
nalysis (Table 3), including adjustment for total duration of
lopidogrel treatment, the incidence rate ratio of the clinical
nd point in the interval of 0 to 90 days compared with the
nterval of 91 to 180 days was 4.20 (95% confidence interval:
.43 to 12.30; p  0.009).
iscussion
n this study we report the clinical outcome of 894 patients
ith ULMCA stenosis treated with PCI. At the 30-day
ollow-up, we observed a 3.3% incidence of cardiac mortal-
ty and a 2.1% incidence of MI, which favorably compare
ith early clinical outcomes of high-risk patients with
LMCA stenosis treated with surgery (8). In contrast, this
ate of 30-day mortality was slightly higher if placed in the
ontext of the general stent experience reported in random-
zed trials (9). However, we must emphasize that not only
atients enrolled in this study had ULMCA stenosis, which
epresents a risk factor per se, but they also presented
igh-risk clinical features because of old age, clinical pre-
entation, high Euroscore, the presence of several comor-
idities, and high incidence of bifurcation lesions. Not
urprisingly, we observed that the highest incidence rate of
ardiac mortality and MI occurred at 30-day follow-up, a
nding that is in line with the concept that the period
mmediately after stenting is the most critical, because of
eriprocedural complications and stent thrombosis. How-
ver, the aim of this study was to investigate whether there
ere other periods at increased risk of cardiac mortality and
I in patients taking dual antiplatelet therapy and after
Figure 3
Adjusted Instantaneous Incidence
Rate/Patient-Days of Cardiac Mortality
and MI After Clopidogrel Discontinuation
The risk of cardiac mortality and myocardial infarction (MI) was
concentrated between 0 and 90 days; this risk abruptly declined thereafter.lopidogrel discontinuation, independent from the 30-day (linical outcome. For this reason, we excluded from the
tatistical analyses all patients who died or had an MI in the
rst 30 days. After censoring these patients, we performed 2
inds of analyses: the first considered the time course of
linical events during the first year of follow-up in patients
aking dual antiplatelet therapy, and the second considered
he time course of clinical events after clopidogrel discon-
inuation. The main finding of this study is that after 30-day
ollow-up there are 2 periods at higher risk of cardiac
ortality and MI: the first occurs when patients are still
aking dual antiplatelet therapy and spans the interval
etween 31 and 180 days after PCI; the second occurs in the
rst 3 months after stopping clopidogrel.
This is the first study to report an uneven distribution of
vents in patients with ULMCA stenosis treated with PCI
uring the first year of follow-up while they are still taking
ual antiplatelet therapy. This uneven distribution of the
linical end point was independent from the 30-day clinical
utcome. Patients with ULMCA stenosis represent a high-
isk cohort of patients; furthermore, most of our patients
resented with acute coronary syndromes and had other
igh-risk clinical features. Because our patient population
as highly peculiar, further investigations should assess
hether these findings are limited to patients with
LMCA stenosis or might be extrapolated to other cate-
ories of patients.
The results of our study might have important clinical
mplications. The observation that the risk of cardiac
ortality and MI was not evenly distributed over time
uring aspirin and clopidogrel treatment but was concen-
rated in the first 6 months warrants a careful surveillance of
hese patients in this period of time and should prompt the
evelopment of new therapeutic strategies that reduce the
isk in this specific interval of time. The end point of this
tudy was the occurrence of cardiac mortality and MI,
vents in which platelet activation might play a major role
10). The occurrence of thrombotic events while patients
ere still taking dual antiplatelet therapy raises the hypoth-
sis that a more intense antiplatelet regimen than that
urrently used might be necessary in this time period (11).
his hypothesis is also confirmed by the observation that
he uneven distribution of events was observed only in
atients with acute coronary syndromes. Whereas patients
ith stable coronary artery disease fared well, presenting
ith 1 clinical end point event between 31 and 180 days and
o events thereafter, patients with acute coronary syndromes
resented with 23 events between 31 and 180 days and only
thereafter. Recurrences in patients with acute coronary
yndromes have been correlated with a persistent activation
f the coagulation system (12) that might last several
onths after the first qualifying episode (13). In this context
f increased thrombin generation and consequent platelet
yper-reactivity, the standard maintenance dose of clopi-
ogrel might not guarantee an adequate platelet inhibition
14) and more powerful antiplatelet drugs might be necessary.
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April 7, 2009:1176–81 Ischemic Events in Left MainAnother intriguing finding of our study was the observa-
ion of a cluster of ischemic events in the first 3 months after
lopidogrel suspension. Although most of the events ob-
erved between 0 and 90 days after clopidogrel suspension
ere in patients who underwent dual antiplatelet therapy for
period 6 months, the multivariable analysis showed that
heir occurrence was independent from duration of dual
ntiplatelet therapy. Similar findings were observed by Ho
t al. (15), who reported an increased incidence of death and
I in the initial 90 days after stopping clopidogrel among
oth medically and PCI-treated patients with acute coro-
ary syndrome. Although the cause of this phenomenon
emains unclear, it might be argued that clopidogrel sus-
ension is associated with a rebound hyperthrombotic state
hat might be responsible for the increased risk of cardiac
ortality and MI (16,17). If the results of our study are
onfirmed by other studies, the modality of drug cessation
hould be reconsidered and alternative strategies such as
apering of clopidogrel or increasing the dose of aspirin
hould be evaluated, at least in high-risk patients like those
ncluded in this analysis.
tudy limitations. This study suffers all limitations com-
on to other retrospective studies. The classification of
vents was made at the individual sites without an adjudi-
ation committee. We do not have data on stent thrombosis
ccording to the Academic Research Consortium definition.
e observed a relative low number of events and therefore
annot exclude overfitting of the statistical models.
eprint requests and correspondence: Dr. Tullio Palmerini,
stituto di Cardiologia, Università di Bologna, Policlinico S. Orsola,
ia Massarenti 9, 40 138 Bologna, Italy. E-mail: tulliopalmerini@
otmail.com.
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